Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1075-1082

  Chang, Yuewen ^a   Zhao, Yongfang ^a   Zhan, Hongsheng ^a   Wei, Xiaoen ^a   Liu, Tianjin ^b   Zheng, Bo ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Shanghai Research Institute of Materials Co   (China)

Author keywords

Bufalin; Cancer stem cells; Osteosarcoma; Sphere culture

Indexed keywords

BUFALIN; CISPLATIN; KI 67 ANTIGEN; MOLECULAR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CELL HMG63; CANCER STEM CELL; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CHINESE MEDICINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; STABLE EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; BUFANOLIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICE; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OSTEOSARCOMA; PEPTIDES;

EID: 84898885936     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1143-y     Document Type: Article

References (36)

1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66(19):9339-44.
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66(19):9339-44.
3. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253-61. (Pubitemid 44427449)
4. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-84. (Pubitemid 46706514)
5. Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC. Cancer stem cells - new and potentially important targets for the therapy of oral squamous cell carcinoma. Oral Dis. 2006;12(5):443-54. (Pubitemid 44252536)
6. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res. 2005;65(19):8944-50. (Pubitemid 41377385)
7. Pérez-Caro M, Cobaleda C, González-Herrero I, Vicente-Dueñas C, Bermejo-Rodríguez C, Sánchez-Beato M, et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J. 2009;28(1):8-20.
8. Vermeulen L, Todaro M, Mello FS, Sprick MR, Kemper K, Alea MP, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci. 2008;105(36):13427-32.
9. Yang YM, Chang JW. Current status and issues in cancer stem cell study. Cancer Investig. 2008;26(7):741-55.
10. Wright MH, Calcagno A, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10(1):R10-R.
11. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006;312(19):3701-10.
12. Fuller J. Stem cell aging and cancer. Sci Aging Knowl Environ. 2006;2006(9):pe12.
13. Lahad JP. Stem cell-ness: a "magic marker" for cancer. J Clin Investig. 2005;115(6):1463-7. (Pubitemid 40814652)
14. Shen S, Yang W, Wang Z, Lei X, Xu L, Wang Y, et al. Tumor-initiating cells are enriched in CD44(hi) population in murine salivary gland tumor. PloS One. 2011;6(8):e23282.
15. Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.
16. Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 2002;95(10):2202-10. (Pubitemid 35253383)
17. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004-11. (Pubitemid 46211380)
18. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33(11):1725-31. (Pubitemid 28129196)
19. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967-76.
20. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, Ghivizzani SC, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009;69(14):5648-55.
21. Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenter. 2007;13(24):3374-9. (Pubitemid 47062250)
22. Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene. 1998;16(6):779-87. (Pubitemid 28076089)
23. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate. 2003;54(2):112-24. (Pubitemid 36120327)
24. Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, et al. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anti Cancer Drugs. 2009;20(1):59-64.
25. Wang J, Yin JQ, Jia Q, Shen JN, Huang G, Xie XB, et al. Bufalin induces apoptosis in osteosarcoma U-2OS and U-2OS methotrexate 300-resistant cell lines in vitro. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2010;32(10):734-8.
26. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14(13):4085-95.
27. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004;16(6):708-12. (Pubitemid 39463123)
28. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Investig. 2011;91(8):1195-205.
29. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 Regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109-23. (Pubitemid 350235025)
30. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26(17):2839-45.
31. Uchida S, Yokoo S, Yanagi Y, Usui T, Yokota C, Mimura T, et al. Sphere formation and expression of neural proteins by human corneal stromal cells in vitro. Invest Ophthalmol Vis Sci. 2005;46(5):1620-5. (Pubitemid 44843595)
32. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci. 2009;106(38):16281-6.
33. Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 2008;99(12):2467-76.
34. Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7):1365-75.
35. Chen Y, Guo Q, Zhang B, Kang M, Xie Q, Wu Y. Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol Lett. 2012;4(4):792-8.
36. Tsai SC, Yang JS, Peng SF, Lu CC, Chiang JH, Chung JG, et al. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol. 2012.